ELTX · Elicio Therapeutics, Inc. · Financials
$2.05
-0.06 (-2.84%)
At close · Sep 11
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway.”View the 10-Q filed Aug 13, 2026
Market Cap
$53.88M
Shares
26.28M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$2.3M
-91.9%
FY2022
Net Income
-$39.57M
+23.8%
FY2025
Gross Margin
100%
+1.5pp
FY2022
Operating Margin
-1031.42%
-892.6pp
FY2022
Diluted EPS
-$2.58
+39.3%
FY2025
Operating Cash Flow
-$36.95M
+0.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $653K | — | — | — | $2.3M | $28.31M | $2.88M | |
| $1.19M | — | — | — | $805K | -$1.85M | -$8.85M | |
| — | — | — | — | $0 | $433K | $1.19M | |
| — | — | — | — | $2.3M | $27.88M | $1.69M | |
| — | — | — | — | 100% | 98.47% | 58.68% | |
| $23.69M | $24.9M | $33.66M | $23.85M | $18.1M | $48.7M | $38.98M | |
| $14.23M | $12.81M | $11.33M | $11.9M | $5.63M | $18.49M | $17.99M | |
| — | — | — | — | $9.2M | $3.2M | — | |
| $37.92M | $37.71M | $44.99M | $35.75M | $23.73M | $67.62M | $58.15M | |
| -$37.92M | -$37.71M | -$44.99M | -$35.75M | -$23.73M | -$39.31M | -$55.27M | |
| — | — | — | — | -1031.42% | -138.84% | -1919.2% | |
| $1.58M | $1.13M | $455K | $1.06M | $3.6M | — | — | |
| $77K | -$1.86M | -$6.91M | $550K | -$4.48M | -$15.27M | -$24.83M | |
| $142K | — | — | — | $151K | -$96K | -$71K | |
| — | -$39.57M | -$51.9M | — | -$38.8M | -$54.57M | -$80.11M | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$37.84M | -$39.57M | -$51.9M | -$35.2M | -$28.21M | -$54.57M | -$80.11M | |
| — | — | — | — | -1225.9% | -192.76% | -2781.49% | |
| -$37.9M | -$39.52M | -$51.88M | -$35.39M | -$28.21M | -$54.34M | -$80.44M | |
| USD/shares | -$2.13 | -$2.58 | -$4.25 | -$6.96 | -$89.27 | -$19.30 | -$54.30 |
| USD/shares | -$2.13 | -$2.58 | -$4.25 | -$6.96 | -$89.27 | -$19.30 | -$54.30 |
| shares | — | 15.31M | 12.2M | 5.06M | 316K | 2.82M | 1.48M |
| shares | 19.24M | 15.31M | 12.2M | 5.06M | 316K | 2.82M | 1.48M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.50×
EV/EBIT
—
Peer median 12.38×
P/E (TTM)
—
Peer median 4.00×
Peer medians compare against the 286 similar-size Biotechnology companies (of 536 listed).
Key facts
CIK
1601485
CUSIP
28657F103
13F (30d)
19 filings
19 filers
Visit website
Investor relations